INDOCO vs VINEETLAB: Stock Comparison

INDOCO REMEDIES vs VINEET LABORATORIESUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

INDOCO REMEDIES is the larger company by market capitalisation. INDOCO REMEDIES shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 7; VINEETLAB leads 2 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOVINEETLAB

Valuation lens

What price are you paying?

Market CapContext only
₹2,421 Cr
₹73 Cr
P/E RatioSame reading
445.9x
P/B RatioSame reading
2.67x
EPSINDOCO has the higher reading
₹7.04
₹0.84
Book ValueContext only
₹100.98
₹23.74
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
INDOCO is the larger company
₹2,421 Cr vs ₹73 Cr
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹0.84
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 11.05%
Qtr Sales Growth
VINEETLAB has stronger quarterly sales growth
214.43% vs 14.31%
Qtr Profit Growth
VINEETLAB has stronger quarterly profit growth
31.66% vs -20.51%
ROE
INDOCO has a higher ROE
-0.51% vs -69.22%
ROCE
INDOCO has a higher ROCE
4.26% vs -11.29%
Net Margin
INDOCO has a higher net margin
-5.31% vs -26.92%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOVINEETLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOVINEETLAB
Live Price₹262.51₹37.37
Day Change-3.69%-0.35%
Volume3.69 L38,381
52-Week High₹332.2₹49.99
52-Week Low₹162.19₹27.96
Distance from 52W High-20.98%-25.25%

Valuation

MetricINDOCOVINEETLAB
Market Cap₹2,421 Cr₹73 Cr
P/E Ratio445.9x
P/B Ratio2.67x
EPS₹7.04₹0.84
Book Value₹100.98₹23.74
Dividend Yield0%0%

Growth

MetricINDOCOVINEETLAB
Revenue Growth (TTM YoY)21.9%11.05%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth14.31%214.43%
Qtr Profit Growth-20.51%31.66%

Profitability & Leverage

MetricINDOCOVINEETLAB
ROE-0.51%-69.22%
ROCE4.26%-11.29%
Net Margin-5.31%-26.92%
Operating Margin4.57%-11.25%
Debt to Equity0.64x2.73x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOVINEETLAB
Promoter Holding58.86%5.98%
FII Holding1.27% 0.33 pp0.5% 0.14 pp
DII Holding17.68% 0.47 pp
Public Holding22.04% 0.14 pp93.52% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and VINEET LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.